Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maria K. Beykirch"'
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/10e92c9dbd7d41deadaab76204795532
Autor:
Thomas Haverkamp, Olivia Bronisch, Thomas Knösel, Carolin Mogler, Wilko Weichert, Thomas Stauch, Claudia Schmid, Claudia Rummeny, Maria K. Beykirch, Petro E. Petrides
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:2647-2655
Acute intermittent porphyria (AIP) is a very rare (orphan) metabolic disorder of porphyrin biosynthesis which is characterized by elevated plasma and urine levels of 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). Patients with this disorder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::531155fafa6a923047854dbc7882799d
https://doi.org/10.1007/s00432-022-04384-5
https://doi.org/10.1007/s00432-022-04384-5
Autor:
Elfriede Schuhmann, Brigitte Molitor, Heike Torkler, Christian Loehr, Maria K. Beykirch, Zahra Obermeier, Michael Klein, Petro E. Petrides
Publikováno v:
Annals of Hematology
Givosiran is a novel approach to treat patients with acute intermittent porphyrias (AIP) by silencing of ∂-ALA-synthase 1, the first enzyme of heme biosynthesis in the liver. We included two patients in the Envision study who responded clinically w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c78cfde2a25f50fad1bd692e35bff1f
https://doi.org/10.1007/s00277-021-04547-3
https://doi.org/10.1007/s00277-021-04547-3
Autor:
Petro E. Petrides, Maria K. Beykirch
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 146:1576-1577
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbf7f8c599b2876820b54fddb2a38e8b
https://doi.org/10.1055/a-1581-1316
https://doi.org/10.1055/a-1581-1316
Publikováno v:
Annals of hematology. 98(12)
In Germany, analyses of clinical and laboratory features of patients with acute porphyrias are only available for hereditary coproporphyria (HCP) but not with other acute porphyrias, acute intermittent porphyria (AIP) and variegate porphyria (VP). Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46d078a36b654ba3c9fae1f9ead78df
https://pubmed.ncbi.nlm.nih.gov/31745600
https://pubmed.ncbi.nlm.nih.gov/31745600
Autor:
Volker Diehl, Jeremy Franklin, Christian Rudolph, Maria K. Beykirch, Juergen Heinz, Michael May, Peter Koch, Andreas Engert, Andreas Josting
Publikováno v:
Journal of Clinical Oncology. 20:221-230
PURPOSE: To evaluate salvage treatment outcome of patients with relapsed Hodgkin’s disease (HD) and to distinguish different risk groups using identified prognostic factors. PATIENTS AND METHODS: From 4,754 patients registered in the German Hodgkin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e77c775d97aa35069687ae4a1d0ef5
https://doi.org/10.1200/jco.20.1.221
https://doi.org/10.1200/jco.20.1.221
Autor:
Norman Willich, Michael Pfreundschuh, Dirk Hasenclever, Andreas Engert, U. Rüffer, Eckhart Dühmke, Susanne Staar, Adelheid Emminger, Richard Greil, Esther Fritsch, Anton Atzinger, Maria K. Beykirch, Ursula Paulus, Susanne Sehlen, Richard Herrmann, B. Lathan, Jürgen Wolf, Axel Georgii, U. Rühl, Peter Lukas, Oana Brosteanu, M. Sieber, Peter Koch, Volker Diehl, Angelika Drochtert, Rolf-Peter Müller, Markus Loeffler, Jeremy Franklin, Hartmut Kirchner
Publikováno v:
Journal of Clinical Oncology. 19:2905-2914
PURPOSE: To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin’s disease (HD). PATIENTS AND METHODS: During 1988 to 1994, pathologically staged patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a1eeffa62c80a8d430bcf8de52fef85
https://doi.org/10.1200/jco.2001.19.11.2905
https://doi.org/10.1200/jco.2001.19.11.2905
Publikováno v:
Blood Cells, Molecules, and Diseases. 24:9-13
Chronic myelogenous leukemia (CML) is usually treated with hydroxyurea or interferon-alpha. In some patients high platelet counts develop although leukocyte counts are well controlled with these drugs. If in such a situation cytoreductive therapy has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee89af099f724a14ee129a59644f7cb5
https://doi.org/10.1006/bcmd.1998.0166
https://doi.org/10.1006/bcmd.1998.0166
Publikováno v:
European journal of haematology. 61(2)
We report on our treatment experience in Germany with anagrelide, a novel platelet lowering agent, in 48 patients (27 females, 21 males) with essential thrombocythaemia. Their age was between 19 and 79 yr when anagrelide therapy was initiated. Sixtee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83719affa5009f9b5ffe1c92737b097
https://pubmed.ncbi.nlm.nih.gov/9714517
https://pubmed.ncbi.nlm.nih.gov/9714517